ArticleDermatology practical & conceptual2025
Predictors of Early Response and Relapse in Chronic Spontaneous Urticaria Treated with Omalizumab: The Role of Age, Sex, Disease Duration, and UAS7.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical and hematological parameters associated with omalizumab response in chronic spontaneous urticaria.Irish journal of medical science · 2026Article
- Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOmalizumab is an established treatment for chronic spontaneous urticaria (CSU), yet variability in therapeutic response remains a clinical challenge. Identifying baseline predictors of early response may help optimize patient selection and management strategies.
objectivesTo evaluate the predictive value of age, sex, baseline disease severity, and disease duration for early response to omalizumab and to assess their relationship with relapse risk.
methodsThis retrospective study included 274 patients with CSU treated with omalizumab between 2011 and 2024. Early response was defined as achieving a UAS7 score <7 at one month. Baseline variables included age, sex, UAS7, and disease duration. Binary logistic regression and ROC curve analyses were conducted to identify independent predictors of early response.
resultsAmong 274 patients (mean age 42.96±15.54 years; 66.4% female), early response was achieved in 37.6%. Early responders had significantly lower baseline UAS7 and shorter disease duration (both P<0.001). Logistic regression confirmed both variables as independent predictors. Age and sex were not independently associated with early response, although univariate analysis showed a higher early response rate in patients aged <45 years. ROC analysis demonstrated strong inverse predictive value for UAS7 (AUC=0.917) and disease duration (AUC=0.940). Relapse risk was significantly lower in females and patients aged <45 years.
conclusionsLower baseline UAS7 and shorter disease duration independently predict early response to omalizumab. Younger age and female sex may be associated with lower relapse risk. These findings support earlier therapeutic intervention in patients with lower disease burden to improve outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.